Raisa Lomanto Silva, MD @RaisaLomanto X Profile

Raisa Lomanto Silva, MD

@RaisaLomanto

Followers

838

Following

6K

Media

72

Statuses

534

MGH Rheumatology Fellow @MGHrheumatology | UPMC Internal Medicine @PittDeptofMed | 🇧🇷| #HealthEquity

Pittsburgh, PA

Joined April 2015

Don't wanna be here? Send us removal request.

Raisa Lomanto Silva, MD

@RaisaLomanto

3 years

Copayment >= $10 is associated with worse adherence to HCQ, AZA, and MMF in individuals with incident SLE! Very grateful for all the support I got and to ACR for giving me the opportunity to share our work in a Plenary session today! #ACR22 https://t.co/gPiA5tArUk

7

56

Ronaldo Correa Fabiano

@Ronaldo_CFF

25 days

🔥 Happy to share our manuscript @LancetRH_Americ WHtR was superior to BMI in predicting atherosclerosis Thiago Mendes @generosoMD @brunohalpern Carolina Janovsky, @carlosmanuelro @rauldsf_santos Isabela Bensenor @PauloLotufo @MBittencourtMD https://t.co/Lw7t5QTN9t

1

2

7

Ronaldo Correa Fabiano

@Ronaldo_CFF

4 months

🔖2025 Annual Alan Lerner Research Symposium @BrighamWomens ❤️‍🔥GlycA Predicts CV Events - VITAL TRIAL Insights Many thanks to my mentor @SamiaMoraMD and her incredible multidisciplinary team!

2

24

Autoinmunes Medicina Interna Parc Taulí

@autoinMI_tauli

6 months

New EULAR/ACR classification criteria for Antisynthetase Syndrome ✅ Anti-ARS antibodies & ILD are top drivers 🧪 ANA, SSA, MSA testing crucial to apply/exclude criteria 🧠 Score ≥5.5 + anti-ARS = definite ASyS ⏩ most weighted items = anti-ARS , ILD, myositis #EULAR2025

1

60

121

Dr Gurdeep S Dulay

@gurdeep_dulay

6 months

Idiopathic inflammatory #myositis -#ILD treatment #EULAR2025

0

65

141

Cardiology Now News

@CardioNowNews

8 months

RIVAWAR Trial: Rivaroxaban Is Comparable to Warfarin for Post-MI Left Ventricular Thrombus Written by @adam_dr_! Summary, analysis and more #ACC25 coverage below! https://t.co/zGtHBUcAm0 @CMichaelGibson @ceciliabahit

0

5

11

MGH Rheumatology

@MGHrheumatology

8 months

Dr. Belen Arevalo & Dr. Zandra Walton present difficult #vasculitis cases from @MassGenBrigham #MGB2025VasculitisPMR #meded #GCA #GPA #cranialnervepalsies #opticneuritis

0

2

Mithu Maheswaranathan, MD

@MithuRheum

8 months

🆕 PJP Prophylaxis in #Rheumatology 🫁 Created with / Review by @CCalabreseDO 🔹Discuss risk factors for PJP infection 🔹Risk Stratify: CD4 count <200 or ALC <500 = ⇡Risk 🔹Review Treatment options and when to stop PPx? #RheumX #RheumTwitter #PulmTwitter #PJP

12

116

293

Elie Naddaf

@ElieNaddaf3

9 months

We have a great program lined up for this upcoming 2-hr webinar on #IBM dedicated to patients and providers, and it is cost free. Hope to see you all ! @MyositisSupport @CureIBM @TheMyositisAssc @aanem @aan

MIHRA

@MIHRAfoundation

9 months

Join #MIHRA Scientific Seminar on IBM❗️ 26Mar 9amEST @ElieNaddaf3 @MymaAlbaydaMD @pedrommcmachado @DutchMyositis @MariannedeViss1 @MerrileeNeedham @HeleneAlex1969 @AANEMorg @TheMyositisAssc @MyositisAust @MyositisSupport @CureIBM @SaketkooMD @mzdimachkie https://t.co/MRO1Lt25Yh

1

2

6

Ariela Orkaby MD MPH

@DrAROrkaby

9 months

Can an eFI be applied to a healthcare system, with incomplete data? Yes! Here we applied the @VAResearch VA-FI to the @MassGenBrigham health record system. Congratulations @bkocharmd @RitchieCS @rbernack and team! https://t.co/AYgLWBaQyY @drandyclegg @AGSJournal @BrighamAging

agsjournals.onlinelibrary.wiley.com

Background Measurement of frailty is limited in clinical practice. Existing electronic frailty indices (eFIs) are derived from routine primary care encounters, with near-complete health condition...

0

10

20

Raisa Lomanto Silva, MD

@RaisaLomanto

11 months

Start spotlight, SO proud 🥹 ⭐️

Mariana Marques, MD

@MCMarquesMD

11 months

Very honored to have been selected as the member spotlight for @carrainc this month. This organization played a very important role in my training, and gave me great opportunities. I’m very glad to be an active part of it 😊 https://t.co/2uPFli0gUf

1

0

3

Minna Kohler, MD, RhMSUS

@minnakohlermd

11 months

#HappyNewYear2025 Excited to receive the hard copy of our new #ultrasound in #rheumatology atlas! Order today https://t.co/azrx4FrtPC @janethyinhmd @MGH_MSUS @PaulDeMarco12 #genekissinmd @minnakohlermd #POCUS #meded #MEDX

1

12

37

Ronaldo Correa Fabiano

@Ronaldo_CFF

1 year

#AHA24 Prior studies: ⬆️vol. physical act (PA) linked ⬆️CAC in suggesting early atherosclerosis Our findings: ⬆️Vol. PA was 🚫 linked w/ ⬆️CAC in asympt w/o CVD ELSA-Brasil cohort Longitudinal athlete-level data is lacking Thx my mentor @MBittencourtMD and all ELSA-Brasil

3

6

27

Gabriela Martinez Zayas, MD

@MartinezZayasMd

1 year

Abstract 333 showed that in a cohort of patients with IIM-ILD increased age, PH, FVC decline at 1 yr, SOB at 2 years were predictors for mortality and lung transplant ! #ACR24 @RheumNow

2

4

29

Raisa Lomanto Silva, MD

@RaisaLomanto

1 year

Flashback circa 2015, best slide at the Great Debate on MCTD! #ACR2024

1

0

9

Didem Saygin, MD

@DidemSayginMD

1 year

Superstar fellow Raisa Silva and incoming resident Manuel Carpio Tumba presenting #ACR24 poster on geographic, racial and ethnic representation in myositis clinical trials 🌟 @RaisaLomanto

0

6

40

Raisa Lomanto Silva, MD

@RaisaLomanto

1 year

In our syst. review.. - Race fully reported in 57.9% RCTs - 42% of RCTs had >20% non-White participants; 21% if excluding RCTs conduted exclusively in Japan - 68.4% RCTs used sex/gender terms per SAGER guidelines Working with the best ⭐️ @DidemSayginMD @SattuiSEMD @manuctumba

3

4

23

Raisa Lomanto Silva, MD

@RaisaLomanto

1 year

Fangirling these two rockstars! A joy to work with @shirikeret and @Irada0720 on ILD transplant-free survival predictors 🫁 @docrota

0

1

11

Mariana Marques, MD

@MCMarquesMD

1 year

I can’t begin to describe how much it filled me with joy to see Dr. Eloisa Bonfa receive the #ACR master designation. Seeing a great clinician and investigator from Brazil show up in that stage; and even more being from my home institution of USP, words can’t describe. 🇧🇷 1/